Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PROF 
Profound Medical Corp (PROF)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: PROF (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $12.1
1 Year Target Price $12.1
| 4 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -24.01% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 180.79M USD | Price to earnings Ratio - | 1Y Target Price 12.1 |
Price to earnings Ratio - | 1Y Target Price 12.1 | ||
Volume (30-day avg) 5 | Beta 0.19 | 52 Weeks Range 3.76 - 8.75 | Updated Date 11/8/2025 |
52 Weeks Range 3.76 - 8.75 | Updated Date 11/8/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.45 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-10-30 | When - | Estimate -0.398 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -624.42% |
Management Effectiveness
Return on Assets (TTM) -53.05% | Return on Equity (TTM) -103.78% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 130622447 | Price to Sales(TTM) 15.27 |
Enterprise Value 130622447 | Price to Sales(TTM) 15.27 | ||
Enterprise Value to Revenue 11.03 | Enterprise Value to EBITDA -5.75 | Shares Outstanding 30053142 | Shares Floating 27532585 |
Shares Outstanding 30053142 | Shares Floating 27532585 | ||
Percent Insiders 17.27 | Percent Institutions 45.72 |
Upturn AI SWOT
Profound Medical Corp
Company Overview
History and Background
Profound Medical Corp. is a medical technology company focused on developing and commercializing incision-free therapies for prostate cancer. Founded in 2008, it aims to transform standards of care in urology.
Core Business Areas
- Therapeutic Solutions: This segment focuses on developing and commercializing TULSA-PRO, an MRI-guided, robotically-driven device for prostate ablation.
Leadership and Structure
The company is led by a management team with experience in medical device development and commercialization, reporting to a board of directors. Exact org chart requires further real-time data.
Top Products and Market Share
Key Offerings
- TULSA-PRO: TULSA-PRO is an incision-free, MRI-guided prostate ablation technology. Market share data for TULSA-PRO is still developing as the technology is relatively new and adoption is growing. Competitors include other minimally invasive prostate cancer treatments such as HIFU, cryotherapy, and radiation therapies (e.g., Accuray (ARAY) with CyberKnife, EDAP TMS S.A. (EDAP)). Limited user data and revenue figures are available. Exact numbers would require access to Profound Medical Corp. financials.
Market Dynamics
Industry Overview
The market for prostate cancer treatment is growing, driven by aging populations and increased awareness. The trend is toward less invasive and more precise therapies.
Positioning
Profound Medical Corp. is positioned as a leader in incision-free prostate ablation with TULSA-PRO, offering a potentially more precise and less morbid alternative to traditional therapies.
Total Addressable Market (TAM)
The prostate cancer treatment market is billions of dollars annually. Profound Medical is targeting a subset of this market focused on less invasive focal therapy, potentially in the hundreds of millions, with continued market penetration.
Upturn SWOT Analysis
Strengths
- Incision-free technology
- MRI-guided precision
- Potential for reduced side effects compared to traditional treatments
- Growing adoption of TULSA-PRO
Weaknesses
- Limited clinical data compared to established treatments
- Dependence on a single product (TULSA-PRO)
- Relatively small size and limited resources
- Commercialization ramp-up risks
Opportunities
- Expanding clinical indications for TULSA-PRO
- Partnerships with hospitals and urology practices
- Increasing awareness of incision-free prostate ablation
- Geographic expansion
Threats
- Competition from established prostate cancer treatments
- Regulatory hurdles
- Reimbursement challenges
- Technological advancements by competitors
Competitors and Market Share
Key Competitors
- ARAY
- EDAP
Competitive Landscape
Profound Medical Corp. has a unique technology with TULSA-PRO, but competes against established players in the prostate cancer treatment market. Advantages include incision-free nature; disadvantages are the limited adoption so far and smaller size of Profound Medical Corp.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by increasing adoption of TULSA-PRO.
Future Projections: Future growth is projected to be driven by further adoption of TULSA-PRO, expanding clinical indications, and geographic expansion.
Recent Initiatives: Recent initiatives include expanding commercialization efforts and conducting clinical trials.
Summary
Profound Medical is a medical device company focused on less invasive prostate cancer treatments. TULSA-PRO is innovative, but the company is small and faces competition from established therapies. Growth depends on TULSA-PRO adoption, clinical data, and securing reimbursement. They need to look out for competitor advancements and regulatory hurdles.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- Industry reports
- Analyst estimates
Disclaimers:
The analysis is based on publicly available information and general industry knowledge. It should not be considered financial advice. Market share data is estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Profound Medical Corp
Exchange NASDAQ | Headquaters Mississauga, ON, Canada | ||
IPO Launch date 2016-06-09 | Chairman of the Board & CEO Dr. Arun Swarup Menawat MBA, Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 142 | Website https://www.profoundmedical.com |
Full time employees 142 | Website https://www.profoundmedical.com | ||
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.